keyword
https://read.qxmd.com/read/38526621/optimal-timing-of-prophylactic-pegylated-g-csf-after-chemotherapy-administration-for-patients-with-cancer-a-systematic-review-and-meta-analysis-from-clinical-practice-guidelines-for-the-use-of-g-csf-2022
#1
JOURNAL ARTICLE
Yukinori Ozaki, Takamichi Yokoe, Tetsuhiro Yoshinami, Kazuki Nozawa, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano
INTRODUCTION: The timing of prophylactic pegylated granulocyte colony-stimulating factor (G-CSF) administration during cancer chemotherapy varies, with Day 2 and Days 3-5 being the most common schedules. Optimal timing remains uncertain, affecting efficacy and adverse events. This systematic review sought to evaluate the available evidence on the timing of prophylactic pegylated G-CSF administration. METHODS: Based on the Minds Handbook for Clinical Practice Guideline Development, we searched the PubMed, Ichushi-Web, and Cochrane Library databases for literature published from January 1990 to December 2019...
March 25, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38523383/the-role-of-proangiogenic-cytokines-in-predicting-sepsis-in-febrile-neutropenic-children-with-cancer
#2
JOURNAL ARTICLE
Selma Çakmakcı, Neriman Sarı, Çiğdem Sönmez, İnci Ergürhan İlhan
BACKGROUND: We assessed the relationship between sepsis occurrence and the serum levels of angiopoietin (Ang-1, Ang-2), vascular endothelial growth factor (VEGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in pediatric patients with cancer-related febrile neutropenia. METHODS: Fifty-two children with malignant tumors who experienced 86 episodes of febrile neutropenia (FN) were examined between June 2016 and June 2018. Each FN episode was considered a separate event and the total number of FNs were recorded (86 FN episodes = FN group)...
2024: Turkish Journal of Pediatrics
https://read.qxmd.com/read/38518846/risk-factors-for-resistant-gram-positive-bacteremia-in-febrile-neutropenic-patients-with-cancer
#3
JOURNAL ARTICLE
Minkyeong Lee, Chan Mi Lee, Ja Min Byun, Dong-Yeop Shin, Youngil Koh, Junshik Hong, Pyoeng Gyun Choe, Wan Beom Park, Nam Joong Kim, Sung-Soo Yoon, Myoung-Don Oh, Chang Kyung Kang, Inho Kim
BACKGROUND: Gram-positive bacteria are frequently resistant to empirical beta-lactams in febrile neutropenic patients with cancer. As microbiology and antibiotic susceptibility changes, we reevaluated the risk factors for resistant Gram-positive bacteremia in febrile neutropenic patients with cancer. METHODS: Episodes of bacteremic febrile neutropenia in Seoul National University Hospital from July 2019 to June 2022 were reviewed. Resistant Gram-positive bacteria were defined as a pathogen susceptible only to glycopeptide or linezolid in vitro (e...
March 20, 2024: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://read.qxmd.com/read/38517658/effectiveness-and-safety-of-primary-prophylaxis-of-granulocyte-colony-stimulating-factor-during-dose-dense-chemotherapy-for-urothelial-cancer-clinical-practice-guidelines-for-the-use-of-g-csf-2022
#4
JOURNAL ARTICLE
Keita Uchino, Shingo Tamura, Shoji Kimura, Keisuke Shigeta, Takahiro Kimura, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Yuji Miura
Granulocyte colony-stimulating factor (G-CSF) decreases the incidence, duration, and severity of febrile neutropenia (FN); however, dose reduction or withdrawal is often preferred in the management of adverse events in the treatment of urothelial cancer. It is also important to maintain therapeutic intensity in order to control disease progression and thereby relieve symptoms, such as hematuria, infection, bleeding, and pain, as well as to prolong the survival. In this clinical question, we compared treatment with primary prophylactic administration of G-CSF to maintain therapeutic intensity with conventional standard therapy without G-CSF and examined the benefits and risks as major outcomes...
March 22, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38512064/early-switch-from-intravenous-to-oral-antibiotic-therapy-in-patients-with-cancer-who-have-low-risk-neutropenic-sepsis-the-easi-switch-rct
#5
RANDOMIZED CONTROLLED TRIAL
Vicky Coyle, Caroline Forde, Richard Adams, Ashley Agus, Rosemary Barnes, Ian Chau, Mike Clarke, Annmarie Doran, Margaret Grayson, Danny McAuley, Cliona McDowell, Glenn Phair, Ruth Plummer, Dawn Storey, Anne Thomas, Richard Wilson, Ronan McMullan
BACKGROUND: Neutropenic sepsis is a common complication of systemic anticancer treatment. There is variation in practice in timing of switch to oral antibiotics after commencement of empirical intravenous antibiotic therapy. OBJECTIVES: To establish the clinical and cost effectiveness of early switch to oral antibiotics in patients with neutropenic sepsis at low risk of infective complications. DESIGN: A randomised, multicentre, open-label, allocation concealed, non-inferiority trial to establish the clinical and cost effectiveness of early oral switch in comparison to standard care...
March 2024: Health Technology Assessment: HTA
https://read.qxmd.com/read/38510886/the-use-of-granulocyte-colony-stimulating-factor-as-primary-prophylaxis-in-patients-undergoing-chemotherapy-an-experience-of-moroccan-oncologists
#6
JOURNAL ARTICLE
Mohamed Kaakoua, Soukayna Boujmadi, Rhizlane Belbaraka, Ismail Essadi
Febrile neutropenia (FN) is a frequent and serious emergency for oncologic patients undergoing chemotherapy. Using granulocyte colony-stimulating factor (G-CSF) as primary prophylaxis of febrile neutropenia is an integral part of the management of cancer patients. Our study aims to identify the challenges that prevent Moroccan oncologists from prescribing G-CSF for primary prevention. Seventy doctors participated in our study, with a participation rate of 35.35%. Twenty-two participants had at least five years of experience in oncology...
February 2024: Curēus
https://read.qxmd.com/read/38506249/-better-at-home-mixed-methods-report-of-intricacies-in-pediatric-febrile-neutropenia-management
#7
JOURNAL ARTICLE
Eleanor T Smeallie, Sung W Choi, Rajen Mody, Timothy C Guetterman, Charles N Nessle
INTRODUCTION: Many febrile neutropenia (FN) episodes are low risk (LR) for severe outcomes and can safely receive less aggressive management and early hospital discharge. Validated risk tools are recommended by the Children's Oncology Group to identify LR FN episodes. However, the complex dynamics of early hospital discharge and burdens faced by caregivers associated with the FN episode have been inadequately described. METHODS: An adapted quality-of-life (QoL) survey instrument was administered by a convergent mixed methods design; qualitative and quantitative data from two sources, the medical record and the mixed methods survey instrument, were independently analyzed prior to linkage and integration...
March 2024: Cancer Medicine
https://read.qxmd.com/read/38473278/cpx-351-pharmacokinetics-and-safety-in-adults-with-hematologic-malignancies-and-renal-function-impairment-phase-1-trial
#8
JOURNAL ARTICLE
Scott R Solomon, Bayard L Powell, Jamie Koprivnikar, Catherine Lai, Heather Male, Laura C Michaelis, Laura F Newell, David Sanford, Jack Jenkins, Amy Zelaya, Sheryl Coppola, Stefan Faderl, Roland B Walter
This open-label phase 1 study (clinicaltrials.gov, NCT03555955) assessed CPX-351 pharmacokinetics (PK) and safety in patients with hematologic malignancies with normal or impaired renal function. Patients were enrolled into three cohorts based on their creatinine clearance (CrCl): ≥90 mL/min (Cohort 1, normal renal function, n = 7), 30 to <59 mL/min (Cohort 2, moderate renal impairment, n = 8), or <30 mL/min (Cohort 3, severe renal impairment, n = 6). Patients received intravenous CPX-351 for initial induction; blood and urine samples were collected for PK analysis...
February 24, 2024: Cancers
https://read.qxmd.com/read/38452788/oral-decitabine-and-cedazuridine-plus-venetoclax-for-older-or-unfit-patients-with-acute-myeloid-leukaemia-a-phase-2-study
#9
JOURNAL ARTICLE
Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, Yesid Alvarado, Alex Bataller, Tareq Abuasab, Rabiul Islam, Kathryn Montalbano, Ghayas Issa, Abhishek Maiti, Musa Yilmaz, Nitin Jain, Lucia Masarova, Steven Kornblau, Elias Jabbour, Guillermo Montalban-Bravo, Caitlin R Rausch, Sherry Pierce, Courtney D DiNardo, Tapan Kadia, Naval Daver, Marina Konopleva, Xuelin Huang, Hagop Kantarjian, Farhad Ravandi
BACKGROUND: Hypomethylating agents combined with venetoclax are effective regimens in patients with acute myeloid leukaemia who are ineligible for intensive chemotherapy. Decitabine and cedazuridine (ASTX727) is an oral formulation of decitabine that achieves equivalent area-under-curve exposure to intravenous decitabine. We performed a single centre phase 2 study to evaluate the efficacy and safety of ASTX727 plus venetoclax. METHODS: This study enrolled patients with newly diagnosed (frontline treatment group) acute myeloid leukaemia who were ineligible for intensive chemotherapy (aged ≥75 years, an Eastern Cooperative Oncology Group [ECOG] performance status of 2-3, or major comorbidities) or relapsed or refractory acute myeloid leukaemia...
March 4, 2024: Lancet Haematology
https://read.qxmd.com/read/38449400/-timing-of-administration-of-pegfilgrastim-and-prophylaxis-for-febrile-neutropenia-for-patients-with-early-breast-cancer-receiving-chemotherapy
#10
JOURNAL ARTICLE
Chihiro Toyoda, Yutaka Mizuno
Febrile neutropenia(FN)causes a prolonged treatment schedule and decreased relative dose intensity(RDI)during cancer chemotherapy, which adversely affects prognosis. In recent years, dose-dense(dd)chemotherapy has been used as adjuvant chemotherapy for patients with breast cancer based on the results of improved disease-free survival according to meta-analysis data. Regarding neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer, taxanes and trastuzumab with the addition of pertuzumab have shown higher pathological complete response rates and elevated incidences of FN...
February 2024: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38446351/sacituzumab-govitecan-a-review-in-unresectable-or-metastatic-hr-her2-breast-cancer
#11
REVIEW
Connie Kang
Sacituzumab govitecan (TRODELVY® ) is a first-in-class trophoblast cell-surface antigen 2 (Trop-2)-directed antibody and topoisomerase I inhibitor conjugate that is approved globally as monotherapy for the treatment of adults with unresectable locally advanced or metastatic, hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-; defined as immunohistochemistry 0, 1+ or 2+ and in situ hybridization-negative) breast cancer who have received endocrine-based therapy and ≥ 2 additional systemic therapies in the advanced setting...
March 6, 2024: Targeted Oncology
https://read.qxmd.com/read/38439907/exploring-immune-related-adverse-events-a-case-of-febrile-neutropenia-in-a-melanoma-patient-receiving-immunotherapy
#12
Melina Yerolatsite, Nanteznta Torounidou, Anna-Lea Amylidi, Fani Kapoulitsa, Eleftherios Kampletsas, George Zarkavelis, Davide Mauri
INTRODUCTION: The introduction of immune checkpoint inhibitors (ICIs) has opened a new chapter in cancer treatment. Nevertheless, their use may result in immune-related adverse events (irAEs) with multifactorial determinants, complex mechanisms, and varying clinical implications. In specific cancer types, like melanoma, irAEs exhibit a complex relationship with patient outcomes. CASE PRESENTATION: We present a case of febrile neutropenia following ICI therapy in a patient with metastatic melanoma, underscoring the intricate clinical landscape associated with irAEs in the context of cancer immunotherapy...
2024: Case Reports in Oncology
https://read.qxmd.com/read/38423663/safety-and-efficacy-of-gemcitabine-plus-cisplatin-against-recurrent-metastatic-nasopharyngeal-carcinoma-a-retrospective-study
#13
JOURNAL ARTICLE
Hiroyuki Kodama, Shigenori Kadowaki, Taiko Nakazawa, Yuki Matsubara, Yukiya Narita, Kazunori Honda, Toshiki Masuishi, Hiroya Taniguchi, Masashi Ando, Yutaro Koide, Hiroyuki Tachibana, Takeshi Kodaira, Michi Sawabe, Hoshino Terada, Shintaro Beppu, Daisuke Nishikawa, Hidenori Suzuki, Nobuhiro Hanai, Kei Muro
BACKGROUND/AIM: Although gemcitabine plus cisplatin (GC) prolongs survival in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) compared with fluorouracil plus cisplatin, no study has evaluated the efficacy and safety of GC in nonendemic regions, including Japan, yet. Therefore, we assessed the safety and efficacy of GC in Japanese patients with R/M NPC. PATIENTS AND METHODS: We retrospectively reviewed patients with R/M NPC who received GC treatment at the Aichi Cancer Center Hospital from January 2017 to March 2020...
March 2024: Anticancer Research
https://read.qxmd.com/read/38384499/ctx-m-tem-and-shv-genes-in-escherichia-coli-klebsiella-pneumoniae-and-enterobacter-spp-isolated-from-hematologic-cancer-patients-with-bacteremia-in-uganda
#14
JOURNAL ARTICLE
Margaret Lubwama, David P Kateete, George Katende, Edgar Kigozi, Jackson Orem, Warren Phipps, Freddie Bwanga
PURPOSE: We determined the phenotypic resistance to third-generation cephalosporins, phenotypic extended spectrum beta-lactamase (ESBL) prevalence, and genotypic prevalence of ESBL-encoding genes blaCTX-M , blaTEM , and blaSHV in Enterobacteriaceae isolated from hematologic cancer patients with febrile neutropenia and bacteremia at the Uganda Cancer Institute (UCI). PATIENTS AND METHODS: Blood cultures from hematologic cancer patients with febrile neutropenia were processed in BACTEC 9120...
2024: Infection and Drug Resistance
https://read.qxmd.com/read/38360906/prophylactic-pegfilgrastim-reduces-febrile-neutropenia-in-ramucirumab-plus-docetaxel-after-chemoimmunotherapy-in-advanced-nsclc-post-hoc-analysis-from-nej051
#15
JOURNAL ARTICLE
Keita Miura, Ou Yamaguchi, Keita Mori, Atsushi Nakamura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara, Kentaro Ito, Akihiko Miyanaga, Daisuke Arai, Hiroaki Kodama, Kunihiko Kobayashi, Kyoichi Kaira
Ramucirumab plus docetaxel (RD) can cause febrile neutropenia (FN), which frequently requires the prophylactic administration of pegfilgrastim. However, the effects of prophylactic pegfilgrastim on FN prevention, therapeutic efficacy, and prognosis after RD have not been fully evaluated in patients with advanced non-small-cell lung cancer (NSCLC). Two hundred and eighty-eight patients with advanced NSCLC who received RD as second-line therapy after platinum-based chemotherapy plus PD-1 blockade were included...
February 15, 2024: Scientific Reports
https://read.qxmd.com/read/38353907/effectiveness-and-safety-of-primary-prophylaxis-with-g-csf-for-lung-cancer-a-systematic-review-and-meta-analysis-to-develop-clinical-practice-guidelines-for-the-use-of-g-csf-2022
#16
JOURNAL ARTICLE
Eiki Ichihara, Nobuaki Ochi, Go Makimoto, Kenichiro Kudo, Daijiro Harada, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Toshio Kubo
BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) is commonly administered to cancer patients undergoing myelosuppressive chemotherapy, especially when incidence rate of febrile neutropenia (FN) surpasses 20%. While primary prophylaxis with G-CSF has been proven effective in preventing FN in patients with cancer, there is limited evidence regarding its efficacy in specifically, lung cancer. Our systematic review focused on the efficacy of G-CSF primary prophylaxis in lung cancer...
February 14, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38348961/docetaxel-cisplatin-and-fluorouracil-with-pegfilgrastim-on-day-3-as-neoadjuvant-chemotherapy-for-esophageal-cancer
#17
JOURNAL ARTICLE
Osamu Maeda, Satoshi Furune, Mitsuro Kanda, Kazushi Miyata, Dai Shimizu, Shizuki Sugita, Kazuki Nishida, Masahiko Ando, Yasuhiro Kodera, Yuichi Ando
PURPOSE: A high risk of febrile neutropenia (FN) from neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for esophageal cancer has been reported. The optimal timing of prophylactic use of pegfilgrastim remains to be elucidated. To evaluate the effect of pegfilgrastim administered on day 3, we conducted a feasibility study. METHODS: Chemotherapy consisted of intravenous administration of docetaxel (70 mg/m2 per day) and cisplatin (70 mg/m2 per day) on day 1 and continuous infusion of 5-fluorouracil (750 mg/m2 per day) on days 1-5...
January 2024: Cancer Medicine
https://read.qxmd.com/read/38339248/nivolumab-plus-5-azacitidine-in-pediatric-relapsed-refractory-acute-myeloid-leukemia-aml-phase-i-ii-trial-results-from-the-therapeutic-advances-in-childhood-leukemia-and-lymphoma-tacl-consortium
#18
JOURNAL ARTICLE
Anupam Verma, Yueh-Yun Chi, Jemily Malvar, Adam Lamble, Sonali Chaudhury, Archana Agarwal, Hong-Tao Li, Gangning Liang, Roy Leong, Patrick A Brown, Joel Kaplan, Eric S Schafer, Tamra Slone, Melinda Pauly, Bill H Chang, Elliot Stieglitz, Alan S Wayne, Nobuko Hijiya, Deepa Bhojwani
Improvements in survival have been made over the past two decades for childhood acute myeloid leukemia (AML), but the approximately 40% of patients who relapse continue to have poor outcomes. A combination of checkpoint-inhibitor nivolumab and azacitidine has demonstrated improvements in median survival in adults with AML. This phase I/II study with nivolumab and azacitidine in children with relapsed/refractory AML (NCT03825367) was conducted through the Therapeutic Advances in Childhood Leukemia & Lymphoma consortium...
January 24, 2024: Cancers
https://read.qxmd.com/read/38320486/-nab-paclitaxel-plus-gemcitabine-and-folfox-in-metastatic-pancreatic-cancer
#19
RANDOMIZED CONTROLLED TRIAL
Alfredo Carrato, Roberto Pazo-Cid, Teresa Macarulla, Javier Gallego, Paula Jiménez-Fonseca, Fernando Rivera, Maria Teresa Cano, Mercedes Rodriguez-Garrote, Carles Pericay, Inmaculada Alés, Laura Layos, Begoña Graña, Vega Iranzo, Inmaculada Gallego, Rocio Garcia-Carbonero, Inmaculada Ruiz de Mena, Carmen Guillén-Ponce, Enrique Aranda
Nab -Paclitaxel plus Gemcitabine and FOLFOXThis randomized, open-label, phase II trial compared nab -paclitaxel/gemcitabine followed by modified FOLFOX versus nab -paclitaxel/gemcitabine alone for the first-line treatment of metastatic pancreatic ductal adenocarcinoma. Patients receiving nab -paclitaxel plus gemcitabine followed by modified FOLFOX-6 (oxaliplatin, leucovorin, and 5-fluorouracil) had a 12-month and 24-month overall survival of 55.3% and 22.4%, respectively, compared with 35.4% and 7.6% in the control group; there was a higher incidence of grade 3 or higher neutropenia and thrombocytopenia...
February 2024: NEJM Evid
https://read.qxmd.com/read/38317981/spectrum-of-infections-in-different-regimens-of-post-induction-chemotherapy-in-acute-myeloid-leukemia-de-novo-a-comparative-retrospective-study
#20
JOURNAL ARTICLE
Haya Majid, Md Masoom, Nitin Bansal, Wasim Ahmad, Mohd Faiyaz Khan, Sadaf Farooqui, Dinesh Bhurani, Mohd Ashif Khan
BACKGROUND: Patients diagnosed with acute myeloid leukemia (AML) face a heightened susceptibility to infections, which significantly elevates their risk of mortality and disability. The intensity of the chemotherapy treatment and its specific focus on inhibiting myeloid cell divisions render patients especially vulnerable, particularly during the early stages of chemotherapy. This vulnerability is compounded by the occurrence of repeated episodes of prolonged neutropenia, leaving patients highly susceptible to infections...
February 15, 2024: Heliyon
keyword
keyword
95633
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.